Aimmune Therapeutics : Nestle Completes Purchase of Aimmune Therapeutics Shares; Plans Merger With Subsidiary

By Joshua Kirby

Nestle SA said Tuesday that it has bought a number of shares in Aimmune Therapeutics Inc., taking its holding in the pharmaceutical company to 84%.

The Swiss food-and-beverage conglomerate said its wholly-owned subsidiary SPN MergerSub had purchased around 43.4 million shares via a tender offer at a price of $34.50 per share. Added to the shares already owned by Nestle and its subsidiaries, it represents around 84% of the outstanding shares in Aimmune Therapeutics, the company said.

SPN MergerSub will be merged with Aimmune Therapeutics, which will continue as the surviving corporation, Nestle said.

Write to Joshua Kirby at [e-mail]

(END) Dow Jones Newswires

10-13-20 0200ET